In Thursday’s Plenary Session at CROI 2019, David Blast, from the University of Liverpool highlighted the drug interactions in the older HIV population, the need for more searchable databases, and which...
Several biomarkers obtained through non-invasive means could help to predict the development of non-alcoholic fatty liver disease in patients living with HIV (PWH), according to recent research.
The FibroScan-AST (FAST) score has been shown to be effective for the risk assessment of non-alcoholic hepatic steatosis (NASH) in patients without HIV, but its effectiveness in HIV+ patients is currently...
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
While neurocognition can increasingly decline with age among individuals with HIV, researchers of a study presented at CROI 2019 determined which factors are connected with neurocognitive decline in the...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection.
...
